• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

SGLT-2 inhibitors as cardioprotective agents in COVID-19.

作者信息

Gupta Kashish, Kunal Shekhar

机构信息

Department of Medicine, SMS Medical College, Jaipur, Rajasthan, India.

Department of Cardiology, SMS Medical College, Jaipur, Rajasthan, India.

出版信息

Heart Lung. 2020 Nov-Dec;49(6):875-876. doi: 10.1016/j.hrtlng.2020.09.002. Epub 2020 Sep 22.

DOI:10.1016/j.hrtlng.2020.09.002
PMID:33010945
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7508492/
Abstract
摘要

相似文献

1
SGLT-2 inhibitors as cardioprotective agents in COVID-19.钠-葡萄糖协同转运蛋白2抑制剂作为COVID-19中的心脏保护剂
Heart Lung. 2020 Nov-Dec;49(6):875-876. doi: 10.1016/j.hrtlng.2020.09.002. Epub 2020 Sep 22.
2
Sodium-glucose Cotransporter 2 Inhibitors and the Risk of Diabetic Ketoacidosis; from Pathophysiology to Clinical Practice.钠-葡萄糖协同转运蛋白2抑制剂与糖尿病酮症酸中毒风险；从病理生理学到临床实践
Cardiovasc Hematol Disord Drug Targets. 2018;18(2):139-146. doi: 10.2174/1871529X18666180206123149.
3
SGLT-2 inhibitors: pharmacokinetics characteristics and effects on lipids.SGLT-2 抑制剂：药代动力学特征及对血脂的影响。
Expert Opin Drug Metab Toxicol. 2018 Nov;14(11):1113-1121. doi: 10.1080/17425255.2018.1541348. Epub 2018 Oct 31.
4
[Outcome studies on SGLT-2 inhibitors].[钠-葡萄糖协同转运蛋白2抑制剂的疗效研究]
Internist (Berl). 2019 Sep;60(9):903-911. doi: 10.1007/s00108-019-0656-x.
5
Comparison of glucose-lowering agents after dual therapy failure in type 2 diabetes: A systematic review and network meta-analysis of randomized controlled trials.二甲双胍单药治疗失效的 2 型糖尿病患者换用不同降糖药物的疗效比较：一项系统评价和网状 Meta 分析的随机对照临床试验研究
Diabetes Obes Metab. 2018 Apr;20(4):985-997. doi: 10.1111/dom.13185. Epub 2018 Jan 8.
6
SGLT-2 inhibitors in Diabetic Kidney Disease: What Lies Behind their Renoprotective Properties?SGLT-2 抑制剂在糖尿病肾病中的作用：它们的肾脏保护特性背后的原理是什么？
Curr Med Chem. 2019;26(29):5564-5578. doi: 10.2174/0929867325666180524114033.
7
Pharmacologic strategies to reduce cardiovascular disease in type 2 diabetes mellitus: focus on SGLT-2 inhibitors and GLP-1 receptor agonists.用于降低 2 型糖尿病患者心血管疾病风险的药物治疗策略：重点关注 SGLT-2 抑制剂和 GLP-1 受体激动剂。
J Intern Med. 2019 Jul;286(1):16-31. doi: 10.1111/joim.12890. Epub 2019 Mar 19.
8
Sodium-glucose cotransporter 2 inhibitors: an evidence-based practice approach to their use in the natural history of type 2 diabetes.钠-葡萄糖协同转运蛋白2抑制剂：基于循证实践的2型糖尿病自然病程中使用方法
Curr Med Res Opin. 2016 May;32(5):907-19. doi: 10.1185/03007995.2016.1151774. Epub 2016 Feb 26.
9
An update on the safety and efficacy of oral antidiabetic drugs: DPP-4 inhibitors and SGLT-2 inhibitors.口服抗糖尿病药物的安全性和疗效更新：DPP-4 抑制剂和 SGLT-2 抑制剂。
Expert Opin Drug Saf. 2019 Aug;18(8):691-701. doi: 10.1080/14740338.2019.1626823. Epub 2019 Jun 7.
10
Promise of SGLT2 Inhibitors in Heart Failure: Diabetes and Beyond.SGLT2抑制剂在心力衰竭中的前景：糖尿病及其他领域
Curr Treat Options Cardiovasc Med. 2017 Mar;19(3):23. doi: 10.1007/s11936-017-0522-x.

引用本文的文献

1
Why have SGLT2 Inhibitors Failed to Achieve the Desired Success in COVID-19?SGLT2 抑制剂为何未能在 COVID-19 中取得预期的成功？
Curr Pharm Des. 2024;30(15):1149-1156. doi: 10.2174/0113816128300162240322075423.
2
Antidiabetic Drug Efficacy in Reduction of Mortality during the COVID-19 Pandemic.抗糖尿病药物在降低 COVID-19 大流行期间死亡率方面的疗效。
Medicina (Kaunas). 2023 Oct 11;59(10):1810. doi: 10.3390/medicina59101810.
3
Evaluating the effects of sodium glucose co-transporter -2 inhibitors from a renin-angiotensin-aldosterone system perspective in patients infected with COVID-19: contextualizing findings from the dapagliflozin in respiratory failure in patients with COVID-19 study.从肾素-血管紧张素-醛固酮系统的角度评估钠-葡萄糖共转运蛋白-2 抑制剂在 COVID-19 感染患者中的作用：从达格列净治疗 COVID-19 呼吸衰竭患者研究中的发现进行背景分析。
Mol Biol Rep. 2022 Mar;49(3):2321-2324. doi: 10.1007/s11033-022-07183-w. Epub 2022 Jan 31.
4
Type 2 Diabetes Mellitus and COVID-19: A Narrative Review.2 型糖尿病与 COVID-19：叙事性综述。
Front Endocrinol (Lausanne). 2021 Mar 31;12:609470. doi: 10.3389/fendo.2021.609470. eCollection 2021.
5
COVID-19 and cardiovascular complications: an update from the underlying mechanism to consequences and possible clinical intervention.新型冠状病毒肺炎与心血管并发症：从潜在机制到后果及可能的临床干预的最新研究进展。
Expert Rev Anti Infect Ther. 2021 Sep;19(9):1083-1092. doi: 10.1080/14787210.2021.1893692. Epub 2021 Mar 5.

本文引用的文献

1
Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19).COVID-19 患者近期康复后的心血管磁共振成像结果。
JAMA Cardiol. 2020 Nov 1;5(11):1265-1273. doi: 10.1001/jamacardio.2020.3557.
2
The Multiple Effects of SGLT2 Inhibitors Suggest Potential Benefit in COVID-19 Patients.钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂的多重效应提示其对新冠病毒疾病（COVID-19）患者可能有益。
Can J Cardiol. 2020 Oct;36(10):1691.e3. doi: 10.1016/j.cjca.2020.07.230. Epub 2020 Jul 24.
3
Acute dapagliflozin administration exerts cardioprotective effects in rats with cardiac ischemia/reperfusion injury.达格列净急性给药对心肌缺血/再灌注损伤大鼠发挥心脏保护作用。
Cardiovasc Diabetol. 2020 Jun 15;19(1):91. doi: 10.1186/s12933-020-01066-9.
4
SGLT-2 inhibitors for COVID-19 - A miracle waiting to happen or just another beat around the bush?用于治疗新型冠状病毒肺炎的钠-葡萄糖协同转运蛋白2抑制剂——是等待发生的奇迹还是又一次的避重就轻？
Prim Care Diabetes. 2020 Oct;14(5):564-565. doi: 10.1016/j.pcd.2020.05.013. Epub 2020 May 28.
5
Lack of Efficacy of SGLT2-i in Severe Pneumonia Related to Novel Coronavirus (nCoV) Infection: No Little Help from Our Friends.钠-葡萄糖协同转运蛋白2抑制剂（SGLT2-i）在新型冠状病毒（nCoV）感染所致重症肺炎中疗效欠佳：朋友们帮不上大忙。
Diabetes Ther. 2020 Jul;11(7):1605-1606. doi: 10.1007/s13300-020-00844-8. Epub 2020 May 23.
6
Cardiovascular system and COVID-19: perspectives from a developing country.心血管系统与2019冠状病毒病：来自一个发展中国家的视角
Monaldi Arch Chest Dis. 2020 May 7;90(2). doi: 10.4081/monaldi.2020.1305.
7
Guidelines for the management of diabetes services and patients during the COVID-19 pandemic.COVID-19 大流行期间糖尿病服务和患者管理指南。
Diabet Med. 2020 Jul;37(7):1087-1089. doi: 10.1111/dme.14316. Epub 2020 May 17.
8
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may be harmful in patients with diabetes during COVID-19 pandemic.在新冠疫情期间，血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂可能对糖尿病患者有害。
Diabetes Metab Syndr. 2020 Jul-Aug;14(4):349-350. doi: 10.1016/j.dsx.2020.04.019. Epub 2020 Apr 15.
9
Clinical Characteristics of Covid-19 in New York City.纽约市新冠肺炎的临床特征
N Engl J Med. 2020 Jun 11;382(24):2372-2374. doi: 10.1056/NEJMc2010419. Epub 2020 Apr 17.
10
Cardioprotection conferred by sodium-glucose cotransporter 2 inhibitors: a renal proximal tubule perspective.钠-葡萄糖共转运蛋白 2 抑制剂的心脏保护作用：从肾脏近端小管的角度来看。
Am J Physiol Cell Physiol. 2020 Feb 1;318(2):C328-C336. doi: 10.1152/ajpcell.00275.2019. Epub 2019 Nov 13.